Observational studyEuropean journal of nuclear medicine and molecular imaging2021
Assessing immune organs on
Observational study in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- LDH and glycolytic activity as predictors of immunotherapy response in gastric cancer: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Applications and research progress of PET/CT in dynamic monitoring of immunotherapy in melanoma.Journal of translational medicine · 2026Review
- Prognostic value of a combined model integrating clinical and PET radiomics parameters in metastatic melanoma: A dual-center retrospective study.Annals of nuclear medicine · 2026Article
- Prognostic Value ofJournal of clinical medicine · 2026Article
- Imaging Immunotherapy.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- The Prognostic Value of Biomarkers Identified by [Diagnostics (Basel, Switzerland) · 2025Article
- Development and validation of a nomogram for incorporatingJournal of thoracic disease · 2024Article
- Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.Translational lung cancer research · 2024Article
- [18F]FDG PET/CT Integration in Evaluating Immunotherapy for Lung Cancer: A Clinician's Practical Approach.Diagnostics (Basel, Switzerland) · 2024Review
- IsCancers · 2024Review
- Elevated splenic 18F-fluorodeoxyglucose positron emission tomography/computed tomography activity is associated with 5-year risk of recurrence in non-metastatic invasive ductal carcinoma of the breast.The British journal of radiology · 2024Article
- Induction of Arterial Inflammation by Immune Checkpoint Inhibitor Therapy in Lung Cancer Patients as Measured by 2-[Life (Basel, Switzerland) · 2024Article
- Application of preoperative NLR-based prognostic model in predicting prognosis of intrahepatic cholangiocarcinoma following radical surgery.Frontiers in nutrition · 2024Article
- Does high [European radiology · 2023Article
- Can physiologic colonic [European journal of nuclear medicine and molecular imaging · 2023Article
- The prognostic value of [European journal of nuclear medicine and molecular imaging · 2023Article
- Metabolic patterns on [European journal of nuclear medicine and molecular imaging · 2023Article
- Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy.European journal of nuclear medicine and molecular imaging · 2023Review
- Interpretation of 2-[European radiology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have significantly improved survival in advanced melanoma. There is a need for robust biomarkers to identify patients who do not respond. We analysed 14 baseline
methodsWe conducted a retrospective monocentric observational study of 29 patients with advanced melanoma who underwent baseline
resultsStrong reproducibility's (intraclass coefficients of correlation (ICC) > 0.90) were observed for spleen anterior SUV
conclusionsSLR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.